UK Veterinary Authority Updates Bioestrovet Swine Injection Guidelines for Pigs Across Farms

The Veterinary Medicines Directorate has updated the Summary of Product Characteristics (SPC) for Bioestrovet Swine 0.0875 mg/ml Solution for Injection, a widely used veterinary product for pigs.

These changes provide clearer guidance for veterinarians on safe administration, potential risks, and expected outcomes when using this product.

The SPC updates are aimed at ensuring animal welfare, minimizing complications, and supporting farmers in achieving predictable results when inducing parturition in sows and gilts.

Key Changes to Usage Guidelines

Several critical updates have been made in Sections 3.3 to 3.8 of the SPC:

• Section 3.3: Bioestrovet Swine should not be used in animals with bronchospasm or gastrointestinal dysmotility.

• Section 3.4: The physiological state of the sow or gilt affects the response to induction. Approximately 95% of treated animals will start farrowing within 36 hours, with most responding within 24±5 hours. Exceptions occur if spontaneous farrowing is imminent.

• Section 3.5: To avoid anaerobic infections caused by vasoconstriction at injection sites, veterinarians should avoid contaminated or wet skin areas. Injection into adipose tissue can reduce absorption. Premature induction may lower piglet birth weights and increase stillbirths. Intravenous administration is prohibited.

• Section 3.7: The injection should not be given to pregnant animals unless the goal is pregnancy termination. Importantly, cloprostenol has no impact on future fertility of treated sows or their offspring.

• Section 3.8: When animals are receiving progestogens, the response to cloprostenol may be reduced.

These adjustments emphasize the importance of careful timing, proper site preparation, and awareness of physiological and pharmacological interactions to ensure safe and effective use.

Why These Updates Matter

Bioestrovet Swine is used to induce farrowing, a process that directly impacts both sow welfare and piglet survival.

Misuse—such as premature induction or injection into improper tissue—can lead to lower birth weights, stillbirths, or reduced absorption of the active compound.

By clarifying contraindications, site preparation procedures, and timing considerations, the SPC updates aim to:

• Improve outcomes for piglets.

• Reduce health risks to sows and gilts.

• Provide veterinarians with precise guidance for safe administration.

Impact and Consequences

Farmers and veterinary teams will need to adjust practices according to the new guidance.

Incorrect timing or administration could have economic consequences due to increased stillbirths or non-viable piglets.

Additionally, adhering to injection site cleaning protocols and avoiding administration in animals with contraindications reduces the risk of infections or complications, ultimately safeguarding both animal welfare and farm productivity.

What’s Next?

Veterinarians should review the updated SPC carefully and ensure all team members involved in pig management are briefed on the changes.

Farms should continue recording gestation lengths accurately to avoid premature inductions and plan treatments according to the updated recommendations.

The VMD will continue publishing all SPC updates, with full details available on the Product Information Database and in the medicine updates section of VMD Connect.

Summary

The Bioestrovet Swine 0.0875 mg/ml Solution for Injection SPC has been updated to clarify safe usage, contraindications, timing of administration, and potential interactions.

Veterinarians and farm staff are encouraged to follow these guidelines closely to optimize animal welfare and farrowing outcomes while minimizing risks to both sows and piglets.

Bulleted Takeaways

• Bioestrovet Swine SPC updated with new guidance on safe administration and contraindications.

• Avoid use in animals with bronchospasm or gastrointestinal dysmotility.

• Farrowing induction effectiveness depends on the physiological state of sows and gilts.

• Injection site must be clean; avoid adipose tissue and intravenous administration.

• Premature induction may reduce piglet birth weight and increase stillbirths.

• Cloprostenol does not affect future fertility of treated sows or their offspring.

• Response may be reduced in animals receiving progestogens.

• All SPC updates are available via the VMD Product Information Database and VMD Connect.

• Adhering to updates ensures improved animal welfare and farm productivity.